Pfizer Takes Impairment Charges On Velsipity And Prevnar 13

 
• By Jessica Merrill

While its new ulcerative colitis drug remains on track to be a blockbuster-sized commercial product, Pfizer said, it took $2.8bn in charges in Q4, including ones related to Velsipity and its pneumococcal vaccine Prevnar 13.

Pfizer
Pfizer reported fourth quarter financials in line with expectations • Source: Shutterstock

More from Earnings

More from Business